Support & Getting Started

Cost & Coverage Support

~90% of patients pay $10 or less with financial assistance offerings¹

New, non-sampled patients can receive
their first
30 days of AUSTEDO XR for free.

Voucher available at
AUSTEDOcardform.com.

Remind pharmacy to apply.

Terms & Conditions apply

Patients may pay as little as $0 per
month for AUSTEDO XR.

Patients must self-enroll at
MySharedSolutions.com.

Visit AUSTEDOcardform.com to send a
link
to patients with more information.

Terms & Conditions apply

Patients who qualify for and utilize LIS
may pay as little as $11.20 per month.¹

Shared Solutions can help patients understand if they qualify. To enroll in Shared Solutions, patients can visit MySharedSolutions.com.

To qualify, patient must:

Apply for assistance
Be a legal US resident
Meet the insurance
eligibility criteria
Be below the income
eligibility limit

To apply, patient must complete the application on MySharedSolutions.com.

~88% of AUSTEDO prescriptions are successfully processed and approved¹

Access for 94% of patients with insurance coverage (commercial, Medicare Part D, and Medicaid)¹
Available at both specialty and retail pharmacies

Request a visit from an Access & Reimbursement Manager to help with prior authorizations, affordability programs, payer coverage, and reimbursement support*

*If you do not have an Access & Reimbursement Manager, reach out to your sales representative.

Prescription
coverage tool

Find health plans that cover AUSTEDO^® XR (deutetrabenazine) extended-release tablets in your state

Enter in a ZIP code or select a state, then select a plan type, select a plan, and click “Search.”

Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming

Commercial
DME MAC
EGWP
Employer
Fed Prog
FEHBP
HIX
IDN/HOSP
MAC A
MAC B
Managed Medicaid
Medicare MA
Medicare PDP
Medicare SN
Medi-Medi
Municipal Plan
PACE
PBM
Pvt HIX
State Medicaid
Union

NA, not available.
Please note that plans may have multiple formularies and they are subject to change by the plan. Please check with the health plan directly to confirm formulary status, requirements, and coverage information for individual patients.
Source: Fingertip Formulary database as of 04/2024.
This information is intended only to show the formulary coverage status for each product and should not be construed to make any comparisons of safety, efficacy, or other clinical outcome.

Patients typically pay less out of pocket vs tetrabenazine^1†

Commercial Insurance Case Study

Dual-eligible with LIS Case Study

Meet Tina

Age: 50
Diagnosed with Huntington’s disease 6 years ago
Recently prescribed AUSTEDO for her chorea symptoms
AUSTEDO is covered in a preferred position on Tina’s commercial healthcare plan
Tina pays $0 OOP for AUSTEDO

$25 OOP cost

– $25 application of Copay Card^‡

$0 net OOP cost

~80% of commercial patients on AUSTEDO will pay $0 out of pocket vs 39% of patients on tetrabenazine^1§

^†Time period: 1/2022 through 2/2023.¹

^‡See Copay Card terms and conditions on AUSTEDOcopayterms.com.

^§Time period: rolling quarter 1/2023.¹

VIEW RESOURCES FOR
YOU & YOUR PATIENTS

LIS, low-income subsidy; OOP, out of pocket.

REFERENCES: 1. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 2. Medicare. Find your level of Extra Help (Part D). Accessed January 9, 2023. https://www.medicare.gov/your-medicare-costs/get-help-paying-costs/find-your-level-of-extra-help-part-d

Important safety information

Depression and Suicidality in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.

Clinical Worsening and Adverse Events in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington’s disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.

Please see full Prescribing Information, including Boxed Warning.

~90% of patients pay $10 or less with financial assistance offerings1

~88% of AUSTEDO prescriptions are successfully processed and approved1

Prescription coverage tool

Find health plans that cover AUSTEDO® XR (deutetrabenazine) extended-release tablets in your state

Find health plans that cover AUSTEDO® XR (deutetrabenazine) extended-release tablets in your state

Patients typically pay less out of pocket vs tetrabenazine1†

~90% of patients pay $10 or less with financial assistance offerings¹

~88% of AUSTEDO prescriptions are successfully processed and approved¹

Prescription
coverage tool

Find health plans that cover AUSTEDO^® XR (deutetrabenazine) extended-release tablets in your state

Find health plans that cover AUSTEDO^® XR (deutetrabenazine) extended-release tablets in your state

Patients typically pay less out of pocket vs tetrabenazine^1†